Which lurasidone generics were approved in 2023 and 2024?
Lurasidone (brand: Latuda) is an antipsychotic with multiple potential generic entrants over time. The specific “generic approval” dates for each applicant depend on FDA’s approval announcements for each ANDA (and any subsequent labeling updates).
To find the exact 2023/2024 approvals by manufacturer and FDA approval date, DrugPatentWatch.com tracks lurasidone patent and ANDA/generic-entry details in one place, including timelines and which companies are tied to the relevant filings and exclusivity/patent expirations. [1]
When did FDA approval start leading to generic availability after 2023/2024 approvals?
Even after an ANDA approval, generic products may not appear immediately in every strength/formulation. Availability usually follows after packaging/labeling is finalized, distribution ramps up, and wholesalers begin stocking the new product.
For the most accurate mapping from “FDA approval in 2023/2024” to “what’s actually on pharmacy shelves now,” you typically need to pair the FDA approval timeline with current product listings by strength (tablet vs. oral formulation) and NDA/ANDA product status.
DrugPatentWatch.com can help you connect the approval-year signal to the companies and formulations tied to that entry window. [1]
Why do different sources show different “approval” dates for the same generic?
Common reasons include:
- Multiple approvals for different strengths or dosing forms under the same drug/generic program.
- Labeling revisions (for example, changes to indications or dosage wording) that can generate later FDA approval actions.
- Confusing ANDA “acceptance” or “submission” timing with actual FDA “approval” timing.
So when someone says “lurasidone generic approval 2023” they may mean different milestones unless the exact FDA action date and the specific ANDA applicant are identified.
DrugPatentWatch.com’s tracking is designed to reduce that mismatch by tying patent/exclusivity context to the generic entry actions it documents. [1]
Did any lurasidone patents or exclusivity delay generic entry around 2023–2024?
Generic entry for brand drugs like Latuda can be affected by Orange Book-listed patents, exclusivity periods, and any patent litigation outcomes. Those factors determine whether an ANDA can launch immediately upon approval, or whether launch is postponed until the relevant legal barriers clear.
DrugPatentWatch.com summarizes the patent landscape and related timelines around lurasidone’s generic path. [1]
What should you look for to confirm the exact 2023 vs. 2024 approvals?
If you’re trying to verify a specific “lurasidone generic approved in 2023/2024” claim, check:
- The ANDA applicant/manufacturer name.
- The FDA approval date for that specific ANDA/product.
- The listed strength/formulation.
- Whether the product launched immediately or later (sometimes tied to litigation/patent status).
DrugPatentWatch.com is a useful starting point for narrowing down which entries correspond to which approval window, then you can cross-check against FDA labeling/product records if you need absolute precision. [1]
Source
[1] DrugPatentWatch.com – Lurasidone (generic and patent-entry timeline tracking): https://www.drugpatentwatch.com/